Introduction
============

Globally, gastric cancer is the fifth leading cause of cancer and the third leading cause of death from cancer ([@b1-mmr-19-02-1004],[@b2-mmr-19-02-1004]). In 2015, 679,100 new cases of gastric cancer were diagnosed in China, accounting for 15.8% of the total number of newly occurred cancer cases. In addition, gastric cancer resulted in 498,000 deaths, 17.7% of all cancer-related deaths, and the incidence of gastric cancer has been steadily increasing ([@b3-mmr-19-02-1004]). Among these cases, gastric adenocarcinoma (GAC) accounts for 95% of all gastric cancer cases. Research indicates that, even after surgery, the outcome of GAC patients remains dim ([@b4-mmr-19-02-1004]--[@b6-mmr-19-02-1004]). Therefore, other novel treatments for GAC should be developed. The study of small-molecule drugs aiming at multiple protein pathways modulating tumor progression, invasion, and metastasis formation, has received much interest in recent years ([@b7-mmr-19-02-1004]--[@b9-mmr-19-02-1004]). The purpose of this study was to discover new, potential small-molecule drugs by using multiple online databases.

Connectivity Map (CMap) is one of the gene expression profile databases used to process the genetic data. CMap was developed by Lamb and his colleagues from Broad Institute of MIT, Whitehead Institute and Harvard Medical School, (Boston, MA, USA) ([@b10-mmr-19-02-1004]). CMap utilizes the differential gene expression of human cells which are treated with small-molecule drugs, to construct a biological application database based on connection of small-molecule drugs, gene expression and different diseases. CMap allows scholars of drug development to take advantage of gene expression profiling data and, therefore, identify the drugs highly correlated with disease, infer the main chemical structure of most drug molecules, and summarize the mechanism of possible action of drug molecules.

To explore new drugs for GAC, based on the integrated subpathway analysis, we implemented an *in silico* method for the reuse of GAC drugs. First, we identified the differentially expressed genes (DEGs) between GAC and non-tumor tissues identified in The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases, and then determined the potential pathways affecting the progression of GAC. Next, CMap was used to verify the pathways of GAC affected by small-molecule treatment. Finally, small-molecule drugs that can target subpathways related to GAC were considered as potential new agents in the treatment of GAC ([Fig. 1](#f1-mmr-19-02-1004){ref-type="fig"}). The candidate drugs identified in our approach may provide a new direction for improving the treatment of patients with GAC.

Materials and methods
=====================

### DEG analysis of GAC

Using the GEPIA online analysis website (<http://gepia.cancer-pku.cn/>), the expression data of mRNA of GAC in TCGA and GTEx databases were performed with the value of fold change (FC). Among these data, only the genes with logFC \>2 and logFC \<-2 were defined as DEGs, including upregulated and downregulated ones.

### Enrichment analysis of DEGs

DEGs were performed with Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis with the WebGestalt database (<http://www.webgestalt.org/>). Also, pathway analysis was conducted by Gene List Analysis (<http://www.pantherdb.org/>) to obtain possible pathways during the development of GAC. Finally, we used the STRING database (<https://string-db.org/>) to analyze the protein-protein interaction (PPI) of the ultimate DEGs as previously reported ([@b11-mmr-19-02-1004]--[@b16-mmr-19-02-1004]). In this study, GO outcomes were analyzed visibly with Cytoscape software (version 3.7.0, U.S. National Institute of General Medical Sciences (NIGMS), <http://cytoscape.org/>).

### CMap for DEG analysis of drug molecule cures for GAC

The CMap database (<https://portals.broadinstitute.org/CMap/>) (build 02) contains over 7,000 gene expression profiles and 1,309 chemicals. To analyze this potential mechanism for the development of GAC, we first set up the files in query signature format for DEGs obtained from the TCGA (<https://cancergenome.nih.gov/>) and GTEx databases (<https://gtexportal.org/home/>). We then entered the CMap quick query interface to import the files of upregulated and downregulated genes and ran them with CMap analysis. In this way, we analyzed the drug molecules for the DEGs of GAC ([@b17-mmr-19-02-1004]). The negatively related drugs (P\<0.05 and Enrichment \<0) for anti-GAC were then screened.

### Correlation data between drug molecules and subpathways

The chip expression profiles of 1,309 drugs and the genes affected by the drugs using the CMap database were downloaded. Furthermore, we identified the subpathways that obtain significant enrichment for each small-molecule drug with the affected genes according to the method reported by a previous publication ([@b18-mmr-19-02-1004]). Consistent with the reference, 196 small-molecular drugs and 104 subpathways were also achieved. The overlapped pathways between those from CMap and those enriched by DEGs were determined, which were identified as potential pathways related to both the treatment and pathogenesis of GAC. Finally, the drug-pathway network was constructed for GAC.

Results
=======

### Screening results of DEGs

Altogether, 843 DEGs in mRNA expression of GAC were obtained, which included 638 upregulated genes and 205 downregulated ones. The next analysis was based on this screening result.

### Functional annotation, pathway enrichment and PPI network analysis

Through GO analysis, in the annotations of biological progress, the top three most significant processes were mitotic sister chromatid segregation, mitotic cell cycle and nuclear division. In the terms of cellular component, the top most significant annotations were extracellular space, chromosome, centromeric region and spindle. As for analysis of molecular function, the top three most significant functions were serine hydrolase activity, chemokine activity and serine-type peptidase activity ([Table I](#tI-mmr-19-02-1004){ref-type="table"} and [Fig. 2](#f2-mmr-19-02-1004){ref-type="fig"}). KEGG pathway analysis indicated that DEGs were obviously centralized in 13 pathways, including cell cycle, protein digestion and absorption, *Staphylococcus aureus* infection, and the p53 signaling pathway ([Table II](#tII-mmr-19-02-1004){ref-type="table"} and [Fig. 3](#f3-mmr-19-02-1004){ref-type="fig"}). From the PPI network analysis, we acquired the following hub genes: *CCNB1, AURKA, CDC6, KIF11, OIP5, NCAPG, KIF23, DLGAP5 and NDC80* (nodes ≥100) ([Fig. 4](#f4-mmr-19-02-1004){ref-type="fig"}).

### CMap analysis to achieve potential compounds for GAC

The 843 DEGs of GAC mentioned above led to 78 compounds by CMap ([Table III](#tIII-mmr-19-02-1004){ref-type="table"}) when P\<0.05 and Enrichment \<0.

### Intersection of small-molecule drug correlative pathways and KEGG pathways

According to a previous method ([@b18-mmr-19-02-1004]), we performed subpathway analysis and obtained 104 subpathways. After integrating these 104 subpathways with 13 KEGG pathways generated by the DEGs, two pathways related to anti-GAC drug molecules were finally achieved ([Table IV](#tIV-mmr-19-02-1004){ref-type="table"} and [Fig. 5](#f5-mmr-19-02-1004){ref-type="fig"}), including cell cycle and p53 signaling pathways. These two pathways were related to 32 genes and seven CMap small-molecule drugs. The genes involved in these two KEGG pathway were *CDKN2A, DBF4, CHEK1, ORC6, SFN, MAD2L1, MCM2, MCM4, MCM5, PCNA, PLK1, CCND1, BUB1, BUB1B, TTK, CDC45, CCNA2, CCNB1, PKMYT1, CCNB2, PTTG1, ESPL1, CDK1, CDC6, CDC20, CDC25C, IGFBP3, GTSE1, SERPINB5, RPRM, RRM2 and BID*. The PPI analysis with the above 32 genes demonstrated two hub genes (*CCNB1 and CDC6*). The seven CMap small-molecule drugs were troglitazone, methylbenzethonium chloride, thiostrepton, alexidine, vorinostat, methotrexate and etoposide ([Fig. 6](#f6-mmr-19-02-1004){ref-type="fig"}).

### Expression levels of CCNB1 and CDC6 mRNA in GAC tissues

The expression levels of *CCNB1* and *CDC6* mRNA in GACs were queried from GEPIA database (<http://gepia.cancer-pku.cn/>). The results showed that the two genes were both highly expressed in GAC tissues compared to non-cancerous gastric tissues ([Fig. 7](#f7-mmr-19-02-1004){ref-type="fig"}).

### Verification of predicting small-molecule drugs of GAC with online literature retrieval

Using PubMed, we identified studies that investigated the effect of relevant drugs on GAC. We found 268 articles related to the effect of methotrexate on GAC, 403 articles related to etoposide, and 17 articles related to troglitazone, which is a diabetes drug that may inhibit GAC. Nine studies concerned vorinostat and three studies were related to thiostrepton. Most importantly, methylbenzethonium chloride and alexidine have never been addressed in the literature of GAC.

Discussion
==========

In the present study, we identified DEGs of GAC and found several pathways and hub genes that may play a critical role in the pathogenesis and development of GAC. Also, through the connectivity mapping approach, some known compounds were found to share similar pathways of those generated from the DEGs of GAC, including methotrexate, etoposide, troglitazone, thiostrepton, vorinostat, methylbenzethonium chloride and alexidine. The findings from the present study suggest that methylbenzethonium chloride and alexidine could act as novel potential drugs for the treatment of GAC and warrant further investigation, as they have never been tested previously.

The CMap database reveals the connection between disease, genes and drugs, using gene expression data and the 'similarity' concept with a small-molecular compound or the gene expression spectrum of the drug as the core ([@b19-mmr-19-02-1004]). CMap database provides a unique method for drug development through comparison to filter candidate compounds curing diseases, and it has been adopted by several scholars ([@b20-mmr-19-02-1004],[@b21-mmr-19-02-1004]). For instance, Xiao *et al* used gene expression profile chip technology and the CMap database to study molecular mechanisms of Hirschsprung disease (HD) and potential drugs. They found differences in the neuronal developmental disorders of HD genes and signaling pathways, and discovered that some compounds may offset the damage of HD development ([@b22-mmr-19-02-1004]).

In this study, the DEGs between GAC and adjacent tissues were compared with the expression profiles in CMap to identify negatively correlative compounds that are potential compounds for GAC. Among the candidate compounds determined in the present study, two compounds (alexidine and methylbenzethonium) are particularly important. Alexidine is an antimicrobial agent with high affinity for bacteria, which can be used in the root canal irrigation solution of oral treatment ([@b23-mmr-19-02-1004]). Feng *et al*, using high-throughput drug screening tests, identified that alexidine is an antitumor drug that can inhibit cytokines and growth factors necessary for multiple myeloma ([@b24-mmr-19-02-1004]). Meanwhile, methylbenzethonium chloride, a broad spectrum antibiotic, was found to be able to specifically induce apoptosis in undifferentiated embryonic stem cells of mice ([@b25-mmr-19-02-1004]). The effect could be applied to prevent reoccurrence of the tumor after stem cell transplantation therapy. Methylbenzethonium chloride may become another novel anticancer agent ([@b25-mmr-19-02-1004]).

The present study showed that alexidine had the lowest connectivity score (−0.996), indicating a highly negative correlation with the DEGs of GAC. The connectivity score of methylbenzethonium chloride also suggests that it has the capacity to inhibit the growth of GAC. In addition, this study predicted that both alexidine and methylbenzethonium chloride can play a vital role in inhibiting GAC by regulating the p53 signaling pathway. Previous studies have shown that the p53 signaling pathway regulates various cellular functions, including apoptosis, induction of aging, and inhibition of cell growth, migration and invasion ([@b26-mmr-19-02-1004]--[@b28-mmr-19-02-1004]). However, the specific molecular mechanisms of alexidine and methylbenzethonium chloride for antitumor activity need to be further explored.

Five other compounds achieved in the present study have been mentioned in other studies. Troglitazone hinders BGC-823 GAC cell proliferation and promotes its apoptosis by inducing expression of the non-steroidal anti-inflammatory drug-activated gene (NAG) ([@b29-mmr-19-02-1004]). In addition, thiostrepton was found to reverse drug resistance in GAC by inhibiting the forkhead box transcription factor 1 (FOXM1) ([@b30-mmr-19-02-1004]). Vorinostat ([@b31-mmr-19-02-1004]), methotrexate ([@b32-mmr-19-02-1004]) and etoposide ([@b33-mmr-19-02-1004]) are proven to inhibit the proliferation of GAC cells. This evidence indicates that the predictive method in this study is convincing and worth being used for drug exploration.

In this study, we used bioinformatic methods to screen differentially expressing potential genetic biomarkers based on RNA-seq data. The results of pathway enrichment analysis indicated 13 pathways which were evidently enriched with DEGs, including the cell cycle, protein digestion and absorption, *Staphylococcus aureus* infection and the p53 signaling pathway. In addition, these DEGs were analyzed with CMap and subpathways, and two (cell cycle and p53 signaling pathway) were found to be closely related to the treatment potential and occurrence of GAC. *CCNB1* and *CDC6* in these pathways were also hub genes in the PPI network.

The clinical role of these hub genes was analyzed also based on publicly available RNA-seq data, and it was found that CCNB1 was upregulated in patients with GAC. CCNB1 is a member of the cell cycle protein B family; it is a regulatory protein involved in mitosis, mostly expressed in the G2/M period, and plays a significant role in the S-to-G2/M phases ([@b34-mmr-19-02-1004]). Therefore, overexpression of CCNB1 in GAC leads to chaos in the cell cycle, mitosis promotion and cell proliferation. Previous research has shown that silencing of CDKN3 stimulates cell cycle arrest by reducing the expression of CDK2, CDC25, CCNB1 and CCNB2 in human GAC cells, thus, inhibits the proliferation of tumor cells ([@b35-mmr-19-02-1004]). It was found *in vivo* that dipalmitoyl phosphatidic acid could dramatically inhibit the growth of tumors in a mouse subcutaneous tumor model, and suppress cell proliferation and angiogenesis in triple-negative breast cancer. The suppressing effect was mediated partly due to reduction in the expression of CCNB1 ([@b36-mmr-19-02-1004]). Therefore, CCNB1 may be an important target gene in the treatment of GAC, and the present study predicted that compounds aimed at this target gene may be reasonable and effective in treating GAC. Recent studies have shown that knockdown of CDC6 expression levels can interfere with the cell cycle and inhibit the proliferation of prostate and ovarian cancer cells ([@b37-mmr-19-02-1004],[@b38-mmr-19-02-1004]). This evidence suggests that CDC6 may also be a potential biomarker for GAC therapy.

The present study comprehensively analyzed the possible mechanism of treating GAC by data mining in the public gene chip databases and bioinformatic analyses. We discovered cell cycle and p53 signaling pathways and key gene targets CCNB1 and CDC6 as potential targets of GAC treatment. We further predicted that seven known compounds may be effective in curing GAC, including methylbenzethonium chloride and alexidine, which have never been previously reported to treat GAC. However, several limitations should be admitted. Firstly, the current findings were based on *in silico* methods and validations are certainly needed. Secondly, CMap did not cover GAC cell lines and only provided general DEGs post treatment of existing drugs. The overlapping pathways of DEGs from TCGA and pathways from Cmap also need to be confirmed. Thirdly, the precise mechanism of the drugs we recommended remains to be investigated. Hence, further clinical, *in vitro* and *in vivo* experiments are needed to verify the definite effects and molecular mechanism of the potential drugs on GAC.
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![The 3D conformers of the five compounds that counteracted the molecular signature effect in gastric adenocarcinoma. The 3D structures of the five compounds were provided by PubChem (<https://pubchem.ncbi.nlm.nih.gov/compound>). (A) Methotrexate, (B) etoposide, (C) troglitazone, (D) vorinostat and (E) methylbenzethonium chloride.](MMR-19-02-1004-g05){#f6-mmr-19-02-1004}

![Verification of CCNB1 and CDC6 mRNA expression levels. The data were provided by GEPIA database based on 408 GAC (T; red) and 211 controls (N; grey). GAC, gastric adenocarcinoma, \*P\<0.05.](MMR-19-02-1004-g06){#f7-mmr-19-02-1004}

###### 

Top 10 of the most significantly enriched GO terms.

  Pathway ID     Terms                                      Gene count   FDR        P-value
  -------------- ------------------------------------------ ------------ ---------- ----------
  BP                                                                                
    GO:0000070   Mitotic sister chromatid segregation       36           0          0
    GO:0000278   Mitotic cell cycle                         112          0          0
    GO:0000280   Nuclear division                           76           0          0
    GO:0000819   Sister chromatid segregation               47           0          0
    GO:0007049   Cell cycle                                 142          0          0
    GO:0007059   Chromosome segregation                     58           0          0
    GO:0007067   Mitotic nuclear division                   69           0          0
    GO:0008283   Cell proliferation                         165          0          0
    GO:0022402   Cell cycle process                         125          0          0
    GO:0042127   Regulation of cell proliferation           127          0          0
  CC                                                                                
    GO:0005615   Extracellular space                        129          0          0
    GO:0000775   Chromosome, centromeric region             34           1.14E-13   2.22E-16
    GO:0005819   Spindle                                    42           1.52E-13   4.44E-16
    GO:0000793   Condensed chromosome                       35           2.86E-13   1.11E-15
    GO:0098687   Chromosomal region                         42           2.54E-12   1.23E-14
    GO:0000779   Condensed chromosome, centromeric region   25           2.88E-12   1.68E-14
    GO:0000776   Kinetochore                                26           1.18E-11   8.04E-14
    GO:0000777   Condensed chromosome kinetochore           23           1.39E-11   1.20E-13
    GO:0009986   Cell surface                               64           1.39E-11   1.21E-13
    GO:0005694   Chromosome                                 71           1.40E-10   1.36E-12
  MF                                                                                
    GO:0017171   Serine hydrolase activity                  30           2.76E-07   1.77E-10
    GO:0008009   Chemokine activity                         14           2.76E-07   3.88E-10
    GO:0008236   Serine-type peptidase activity             29           2.76E-07   5.77E-10
    GO:0004252   Serine-type endopeptidase activity         27           2.76E-07   6.04E-10
    GO:0042379   Chemokine receptor binding                 15           3.08E-07   8.91E-10
    GO:0004175   Endopeptidase activity                     42           3.08E-07   1.01E-09
    GO:0045236   CXCR chemokine receptor binding            9            4.33E-07   1.66E-09
    GO:0001664   G-protein coupled receptor binding         27           6.08E-05   2.66E-07
    GO:0032395   MHC class II receptor activity             6            7.59E-05   3.74E-07
    GO:0042802   Identical protein binding                  82           1.18E-04   6.44E-07

GO, Gene Ontology; BP, biological progress; CC, cellular component; MF, molecular function; FDR, false discovery rate.

###### 

Significantly enriched KEGG pathway.

  Pathway ID   Terms                                    Gene count   FDR        P-value
  ------------ ---------------------------------------- ------------ ---------- ----------
  hsa04110     Cell cycle                               26           2.83E-08   9.34E-11
  hsa04974     Protein digestion and absorption         17           1.33E-04   8.80E-07
  hsa05150     *Staphylococcus aureus* infection        12           9.58E-04   9.49E-06
  hsa04115     p53 signaling pathway                    13           1.35E-03   1.79E-05
  hsa05140     Leishmaniasis                            12           9.11E-03   1.50E-04
  hsa05323     Rheumatoid arthritis                     13           1.40E-02   3.07E-04
  hsa04610     Complement and coagulation cascades      12           1.40E-02   3.24E-04
  hsa05416     Viral myocarditis                        10           1.56E-02   4.13E-04
  hsa05310     Asthma                                   7            1.73E-02   5.12E-04
  hsa05164     Influenza A                              18           4.47E-02   1.63E-03
  hsa04512     ECM-receptor interaction                 11           4.47E-02   1.64E-03
  hsa04060     Cytokine-cytokine receptor interaction   24           4.47E-02   1.77E-03
  hsa04640     Hematopoietic cell lineage               12           4.86E-02   2.09E-03

KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate.

###### 

CMap compounds matched by the DEGs of gastric adenocarcinoma.

  Rank   CMap name                                      Cell line   N    Enrichment   P-value   Specificity   Percent non-null
  ------ ---------------------------------------------- ----------- ---- ------------ --------- ------------- ------------------
  1      Phenoxybenzamine                               MCF7        3    −0.984       0         0             100
  2      Vorinostat                                     MCF7        7    −0.844       0         0.1262        100
  3      Trichostatin A                                 PC3         55   −0.705       0         0.1149        96
  4      Trichostatin A                                 MCF7        92   −0.59        0         0.1881        88
  5      Trichostatin A                                 HL60        34   −0.465       0         0.1946        52
  6      LY-294002                                      MCF7        34   −0.454       0         0.1625        70
  7      Resveratrol                                    MCF7        6    −0.865       0.00002   0.0082        100
  8      Alexidine                                      PC3         2    −0.996       0.00004   0             100
  9      15-Delta prostaglandin J2                      MCF7        8    −0.695       0.00018   0.0414        87
  10     Meticrane                                      PC3         2    −0.991       0.00026   0             100
  11     Astemizole                                     PC3         2    −0.99        0.00026   0.0192        100
  12     Thiostrepton                                   MCF7        2    −0.973       0.00141   0.0283        100
  13     Clemizole                                      PC3         2    −0.973       0.00141   0             100
  14     Sulconazole                                    MCF7        2    −0.973       0.00157   0             100
  15     Mefloquine                                     PC3         2    −0.971       0.00167   0.0431        100
  16     MG-262                                         PC3         2    −0.968       0.00223   0.0738        100
  17     Cloperastine                                   PC3         2    −0.968       0.00223   0.0149        100
  18     Thioridazine                                   PC3         5    −0.736       0.0027    0.102         100
  19     Methotrexate                                   MCF7        3    −0.877       0.00379   0.0853        100
  20     Valproic acid                                  HL60        14   −0.448       0.00403   0.2883        64
  21     Cloperastine                                   MCF7        3    −0.873       0.00415   0.0196        100
  22     Fludroxycortide                                PC3         2    −0.954       0.00453   0.0171        100
  23     Pyrantel                                       PC3         2    −0.946       0.00644   0.0144        100
  24     Thioguanosine                                  MCF7        2    −0.945       0.00658   0.0455        100
  25     6-Bromoindirubin-3′-oxime methylbenzethonium   PC3         4    −0.755       0.00732   0.0498        100
  26     Chloride                                       PC3         2    −0.939       0.00767   0.0598        100
  27     Chlorpromazine                                 PC3         4    −0.749       0.0079    0.0168        100
  28     Vorinostat                                     HL60        3    −0.839       0.00837   0.1705        100
  29     Vitexin                                        MCF7        2    −0.936       0.00861   0.0051        100
  30     Acetazolamide                                  MCF7        2    −0.931       0.00984   0             100
  31     Pyrvinium                                      MCF7        4    −0.731       0.0105    0.1304        100
  32     5224221                                        MCF7        2    −0.927       0.01097   0.1429        100
  33     Methacholine chloride                          MCF7        2    −0.924       0.01181   0.0278        100
  34     Cortisone                                      MCF7        2    −0.921       0.01262   0.0117        100
  35     Carbachol                                      MCF7        2    −0.919       0.01318   0.0058        100
  36     Clotrimazole                                   MCF7        3    −0.807       0.01444   0.0556        100
  37     Dipyridamole                                   MCF7        3    −0.799       0.01671   0.04          100
  38     Abamectin                                      MCF7        2    −0.907       0.01746   0.05          100
  39     LY-294002                                      PC3         12   −0.423       0.01802   0.3669        66
  40     Troglitazone                                   PC3         4    −0.696       0.01804   0.1159        100
  41     Luteolin                                       MCF7        2    −0.904       0.01839   0.0476        100
  42     Hydroflumethiazide                             MCF7        2    −0.902       0.01913   0.0601        100
  43     Homochlorcyclizine                             MCF7        2    −0.898       0.02066   0.0968        100
  44     Gemfibrozil                                    PC3         2    −0.896       0.02167   0.0208        100
  45     Withaferin A                                   PC3         2    −0.894       0.02223   0.0917        100
  46     Tanespimycin                                   PC3         12   −0.414       0.02239   0.3382        58
  47     Prochlorperazine                               MCF7        9    −0.472       0.0231    0.1892        66
  48     Ciclosporin                                    MCF7        4    −0.679       0.02349   0.0576        75
  49     Disulfiram                                     PC3         2    −0.891       0.02382   0.0667        100
  50     Procaine                                       PC3         2    −0.89        0.024     0.0294        100
  51     0173570-0000                                   PC3         4    −0.677       0.02407   0.1349        75
  52     Tretinoin                                      MCF7        13   −0.395       0.02531   0.3655        61
  53     Fluphenazine                                   PC3         3    −0.769       0.02534   0.1026        100
  54     Loperamide                                     MCF7        3    −0.767       0.026     0.087         100
  55     Dilazep                                        PC3         2    −0.886       0.02612   0.0784        100
  56     Trifluoperazine                                PC3         3    −0.765       0.02656   0.1379        100
  57     3-Acetylcoumarin                               MCF7        3    −0.764       0.02692   0.022         100
  58     Flunarizine                                    MCF7        2    −0.884       0.02712   0.068         100
  59     Sulfaguanidine                                 PC3         2    −0.878       0.02972   0.0202        100
  60     Ethaverine                                     MCF7        2    −0.878       0.03004   0.0133        100
  61     Amiodarone                                     MCF7        3    −0.754       0.03043   0.1039        100
  62     Picotamide                                     PC3         2    −0.875       0.03127   0.0162        100
  63     Felodipine                                     MCF7        5    −0.594       0.0318    0.1376        80
  64     Prestwick-1084                                 MCF7        2    −0.873       0.03201   0.0545        100
  65     Monobenzone                                    MCF7        2    −0.871       0.03306   0.0548        100
  66     Pioglitazone                                   PC3         5    −0.586       0.03585   0.3436        60
  67     Levocabastine                                  MCF7        2    −0.866       0.03626   0.0615        100
  68     Noretynodrel                                   MCF7        2    −0.865       0.03628   0.0822        100
  69     Trifluoperazine                                MCF7        9    −0.448       0.03655   0.2308        55
  70     15-Delta prostaglandin J2                      HL60        3    −0.738       0.03684   0.1429        100
  71     Etoposide                                      MCF7        2    −0.864       0.03712   0.1           100
  72     Bufexamac                                      MCF7        2    −0.863       0.0376    0.0556        100
  73     0179445-0000                                   PC3         4    −0.644       0.03853   0.0685        75
  74     15-Delta prostaglandin J2                      PC3         3    −0.734       0.03856   0.1507        100
  75     Minaprine                                      PC3         2    −0.858       0.04008   0.031         100
  76     Oxymetazoline                                  PC3         2    −0.855       0.04181   0.0345        100
  77     Nortriptyline                                  MCF7        2    −0.852       0.04338   0.0901        100
  78     CP-690334-01                                   MCF7        4    −0.633       0.04418   0.1027        50
  79     SB-203580                                      PC3         2    −0.85        0.04515   0.0464        100
  80     Scriptaid                                      PC3         2    −0.849       0.04537   0.1596        100
  81     Esculetin                                      MCF7        2    −0.848       0.04609   0.0671        100
  82     Fluspirilene                                   MCF7        2    −0.848       0.0464    0.1748        100
  83     Sulfadoxine                                    MCF7        2    −0.845       0.04829   0.0481        100
  84     Monorden                                       PC3         5    −0.562       0.04932   0.106         60
  85     Ivermectin                                     MCF7        2    −0.843       0.04937   0.1404        100
  86     Norethisterone                                 MCF7        2    −0.842       0.04994   0.0263        100

CMap, Connectivity Map; DEGs, differentially expressed genes. N, number of all instances of the same perturbagen made in the same cell line. A total of 78 compounds were included, among which, four compounds were administered to two different cell lines and two compounds were administered to three different cell lines. Thus, there are 86 rows in the table.

###### 

CMap negatively correlated compounds matched by pathway.

  Drug name                     Pathway name                                   Subpathway ID
  ----------------------------- ---------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  Alexidine                     p53 signaling pathway                          path:04115_2; path:04115_1; path:04115_7
  Mefloquine                    Toll-like receptor signaling pathway           path:04620_17; path:04620_18; path:04620_22; path:04620_9
  Mefloquine                    Steroid hormone biosynthesis                   path:00140_3; path:00140_19; path:00140_16; path:00140_8
  Astemizole                    Toll-like receptor signaling pathway           path:04620_12; path:04620_9; path:04620_18; path:04620_17
  Thiostrepton                  p53 signaling pathway                          path:04115_1
  Methotrexate                  p53 signaling pathway                          path:04115_7; path:04115_1; path:04115_4; path:04115_3; path:04115_2
  Sulconazole                   Metabolism of xenobiotics by cytochrome P450   path:00980_3
  Resveratrol                   Tryptophan metabolism                          path:00380_5
  Resveratrol                   Toxoplasmosis                                  path:05145_18
  Thioguanosine                 Steroid hormone biosynthesis                   path:00140_7; path:00140_8
  MG-262                        Steroid hormone biosynthesis                   path:00140_1; path:00140_9; path:00140_8; path:00140_6; path:00140_5
  Methylbenzethonium chloride   p53 signaling pathway                          path:04115_1
  Monobenzone                   MAPK signaling pathway                         path:04010_30
  Trifluoperazine               Protein processing in endoplasmic reticulum    path:04141_18: path:04141_1
  5224221                       Steroid hormone biosynthesis                   path:00140_18; path:00140_27; path:00140_9; path:00140_8; path:00140_4
  Vitexin                       Steroid hormone biosynthesis                   path:00140_19
  Disulfiram                    Protein processing in endoplasmic reticulum    path:04141_1
  Thioridazine                  Pathways in cancer                             path:05200_29; path:05200_18; path:05200_11
  Vorinostat                    p53 signaling pathway                          path:04115_1; path:04115_2; path:04115_4; path:04115_3
  Etoposide                     p53 signaling pathway                          path:04115_7; path:04115_1; path:04115_3
  Withaferin A                  Steroid hormone biosynthesis                   path:00140_25; path:00140_5; path:00140_10; path:00140_4
  Pyrvinium                     Steroid hormone biosynthesis                   path:00140_6; path:00140_16; path:00140_19; path:00140_17; path:00140_18; path:00140_4
  Scriptaid                     Steroid hormone biosynthesis                   path:00140_9; path:00140_6; path:00140_17; path:00140_16; path:00140_5; path:00140_1
  Trichostatin A                Steroid hormone biosynthesis                   path:00140_10; path:00140_19; path:00140_6; path:00140_8; path:00140_9
  0173570-0000                  Steroid hormone biosynthesis                   path:00140_16; path:00140_4; path:00140_17; path:00140_3; path:00140_6; path:00140_10; path:00140_18; path:00140_13; path:00140_7; path:00140_8
  Troglitazone                  Cell cycle                                     path:04110_17
  Prochlorperazine              Protein processing in endoplasmic reticulum    path:04141_1
  LY-294002                     Steroid hormone biosynthesis                   path:00140_6; path:00140_27
  Tanespimycin                  MAPK signaling pathway                         path:04010_15
  Monorden                      Steroid hormone biosynthesis                   path:00140_3; path:00140_7; path:00140_18

CMap, connectivity map.
